HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results, emphasizing the launch of its initial commercial partnerships in key U.S. markets, advancements in its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds. The company reported a first-quarter net loss of $4.7 million, improved from $5.5 million in the prior-year period, with research and development expenses declining year over year as HeartBeam continued advancing commercialization of its FDA-cleared cardiac monitoring platform.
HeartBeam, a medical technology company, is developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians can identify cardiac health trends and acute conditions and direct patients to appropriate care outside a medical facility. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025.
During the first quarter, HeartBeam focused on building commercial partnerships to bring its technology to patients and providers. While specific partners were not named, the company highlighted progress in key U.S. markets. The $11.5 million public offering in April provides additional capital to support these commercial efforts and ongoing development of its heart attack detection and ECG patch initiatives.
The company holds over 20 issued patents related to its technology. For more details on the intended use of its technology, refer to the cleared indications for use at HeartBeam Indications for Use. The full press release is available at https://ibn.fm/guMCF.
